A randomised phase II and pharmacokinetic study of oral ZD1839 given continuously with oxaliplatin or cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Study identifier:1839IL/0058

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised phase II and pharmacokinetic study of oral ZD1839 given continuously with oxaliplatin or cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Medical condition

head and neck cancer

Phase

Phase 2

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Feb 2002
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria